Pluristem Therapeutics Company Profile (NASDAQ:PSTI)

About Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics logoPluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PSTI
  • CUSIP: N/A
  • Web: www.pluristem.com
Capitalization:
  • Market Cap: $135.83 million
  • Outstanding Shares: 80,723,000
Average Prices:
  • 50 Day Moving Avg: $1.40
  • 200 Day Moving Avg: $1.35
  • 52 Week Range: $1.04 - $1.85
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.92
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.37 per share
  • Price / Book: 3.81
Profitability:
  • EBIDTA: ($25,400,000.00)
  • Return on Equity: -75.68%
  • Return on Assets: -62.58%
Debt:
  • Current Ratio: 4.27%
  • Quick Ratio: 4.27%
Misc:
  • Average Volume: 326,284 shs.
  • Beta: 0.12
  • Short Ratio: 2.87
 

Frequently Asked Questions for Pluristem Therapeutics (NASDAQ:PSTI)

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its quarterly earnings results on Thursday, November, 6th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.04. The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million. View Pluristem Therapeutics' Earnings History.

Where is Pluristem Therapeutics' stock going? Where will Pluristem Therapeutics' stock price be in 2017?

3 analysts have issued 1-year price objectives for Pluristem Therapeutics' stock. Their forecasts range from $3.00 to $6.00. On average, they expect Pluristem Therapeutics' share price to reach $4.17 in the next twelve months. View Analyst Ratings for Pluristem Therapeutics.

What are analysts saying about Pluristem Therapeutics stock?

Here are some recent quotes from research analysts about Pluristem Therapeutics stock:

  • 1. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (4/13/2017)
  • 2. Maxim Group analysts commented, "A more comprehensive black box warning added to fluoroquinolone labels. Yesterday, the FDA issued a Drug Safety Communication that it had approved an updated safety label for all fluoroquinolone antibacterial drugs to include an updated Boxed Warning about the risk of disabling and potentially irreversible serious reactions that can occur together. This action by the FDA is a follow-up to a May 12, 2016, drug safety communication requiring the drug labels and Medication Guides for all fluoroquinolones to include a revised Boxed Warnings, which in turn is the result of an Advisory Committee meeting held last November on the safety of this drug class. What appears to be new here is the addition of a statement advising restricted use of fluoroquinolones for patients who lack alternative treatment options for indications, such as uncomplicated urinary tract infection (uUTIs), acute bacterial exacerbations of chronic bronchitis (ABECB), and acute bacterial sinusitis (ABS)." (7/27/2016)

Are investors shorting Pluristem Therapeutics?

Pluristem Therapeutics saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 1,209,736 shares, an increase of 53.7% from the March 31st total of 786,980 shares. Based on an average daily trading volume, of 603,257 shares, the short-interest ratio is presently 2.0 days. Approximately 1.4% of the shares of the stock are sold short.

Who are some of Pluristem Therapeutics' key competitors?

Who owns Pluristem Therapeutics stock?

Pluristem Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.62%), Menora Mivtachim Holdings LTD. (1.04%), UBS Group AG (0.22%), California Public Employees Retirement System (0.19%), Oppenheimer & Co. Inc. (0.13%) and Jane Street Group LLC (0.11%). Company insiders that own Pluristem Therapeutics stock include Doron Shorrer, Israel Ben-Yoram, Yaky Yanay and Zami Aberman. View Institutional Ownership Trends for Pluristem Therapeutics.

Who sold Pluristem Therapeutics stock? Who is selling Pluristem Therapeutics stock?

Pluristem Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Pluristem Therapeutics.

Who bought Pluristem Therapeutics stock? Who is buying Pluristem Therapeutics stock?

Pluristem Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Renaissance Technologies LLC, Jane Street Group LLC and Harel Insurance Investments & Financial Services Ltd.. Company insiders that have bought Pluristem Therapeutics stock in the last two years include Doron Shorrer, Israel Ben-Yoram, Yaky Yanay and Zami Aberman. View Insider Buying and Selling for Pluristem Therapeutics.

How do I buy Pluristem Therapeutics stock?

Shares of Pluristem Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pluristem Therapeutics stock cost?

One share of Pluristem Therapeutics stock can currently be purchased for approximately $1.41.

Analyst Ratings

Consensus Ratings for Pluristem Therapeutics (NASDAQ:PSTI) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $4.17 (195.51% upside)

Analysts' Ratings History for Pluristem Therapeutics (NASDAQ:PSTI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Maxim GroupReiterated RatingHoldLowView Rating Details
5/15/2017HC WainwrightReiterated RatingBuy$3.50LowView Rating Details
1/10/2017FBR & CoReiterated RatingBuyN/AView Rating Details
8/14/2015MLV & Co.Reiterated RatingBuy$6.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Pluristem Therapeutics (NASDAQ:PSTI)
Earnings by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)
Earnings History by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2014($0.13)($0.09)$0.10 million$0.10 millionViewN/AView Earnings Details
10/6/2014($0.13)($0.09)ViewN/AView Earnings Details
9/11/2014($0.15)($0.09)$0.10 million$0.09 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.14)$0.20 million$0.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pluristem Therapeutics (NASDAQ:PSTI)
Current Year EPS Consensus Estimate: $-0.32 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS

Dividends

Dividend History for Pluristem Therapeutics (NASDAQ:PSTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Pluristem Therapeutics (NASDAQ:PSTI)
Insider Ownership Percentage: 8.17%
Institutional Ownership Percentage: 3.05%
Insider Trades by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)
Institutional Ownership by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)
Insider Trades by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2016Zami AbermanCEOBuy5,000$1.33$6,650.00View SEC Filing  
2/18/2016Yaky YanayCFOBuy5,000$1.20$6,000.00View SEC Filing  
2/16/2016Yaky YanayCFOBuy15,000$0.95$14,250.00View SEC Filing  
2/15/2016Doron ShorrerDirectorBuy12,346$0.81$10,000.26View SEC Filing  
2/12/2016Yaky YanayCFOBuy5,000$0.83$4,150.00View SEC Filing  
2/11/2016Israel Ben-YoramDirectorBuy10,000$0.79$7,900.00View SEC Filing  
2/11/2016Zami AbermanCEOBuy31,000$0.80$24,800.00View SEC Filing  
11/16/2015Yaky YanayCFOBuy10,000$1.52$15,200.00View SEC Filing  
11/16/2015Zami AbermanCEOBuy9,900$1.49$14,751.00View SEC Filing  
9/21/2015Israel Ben-YoramDirectorSell30,000$2.10$63,000.00View SEC Filing  
9/21/2015Yaky YanayCFOBuy10,000$2.11$21,100.00View SEC Filing  
9/21/2015Zami AbermanCEOBuy25,500$2.11$53,805.00View SEC Filing  
9/16/2015Yaky YanayCFOBuy10,000$2.12$21,200.00View SEC Filing  
9/15/2015Zami AbermanCEOBuy25,000$2.11$52,750.00View SEC Filing  
11/11/2014Yaky YanayCOOBuy11,000$2.62$28,820.00View SEC Filing  
11/11/2014Zami AbermanCEOBuy13,000$2.64$34,320.00View SEC Filing  
9/22/2014Yaky YanayCOOBuy11,000$2.95$32,450.00View SEC Filing  
9/22/2014Zami AbermanCEOBuy5,000$2.92$14,600.00View SEC Filing  
9/21/2014Zami AbermanCEOBuy5,000$2.96$14,800.00View SEC Filing  
9/17/2014Israel Ben-YoramDirectorBuy5,000$2.82$14,100.00View SEC Filing  
9/16/2014Boaz Gur-LavieCFOBuy3,478$2.84$9,877.52View SEC Filing  
9/16/2014Yaky YanayCOOBuy10,000$2.85$28,500.00View SEC Filing  
9/16/2014Zami AbermanCEOBuy15,000$2.80$42,000.00View SEC Filing  
6/18/2014Mark GermainDirectorSell43,215$3.12$134,830.80View SEC Filing  
1/17/2014Israel Ben-YoramDirectorSell35,625$4.51$160,668.75View SEC Filing  
1/13/2014Israel Ben-YoramDirectorSell26,453$4.29$113,483.37View SEC Filing  
1/13/2014Yaky YanayCFOSell69,850$4.29$299,656.50View SEC Filing  
1/9/2014Yaky YanayCFOSell30,150$4.25$128,137.50View SEC Filing  
1/8/2014Israel Ben-YoramDirectorSell44,797$4.12$184,563.64View SEC Filing  
11/11/2013Nachum RosmanDirectorSell67,244$3.27$219,887.88View SEC Filing  
9/12/2013Israel Ben-YoramDirectorSell52,000$3.07$159,640.00View SEC Filing  
5/20/2013Israel Ben-YoramDirectorSell45,429$3.03$137,649.87View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Pluristem Therapeutics (NASDAQ:PSTI)
Latest Headlines for Pluristem Therapeutics (NASDAQ:PSTI)
Source:
DateHeadline
americanbankingnews.com logoPluristem Therapeutics Inc. (PSTI) Receives "Hold" Rating from Maxim Group
www.americanbankingnews.com - May 23 at 7:28 PM
globenewswire.com logoPluristem Provides Shareholder Update on Corporate and Clinical Developments - GlobeNewswire (press release)
globenewswire.com - May 22 at 9:29 AM
finance.yahoo.com logoPluristem Provides Shareholder Update on Corporate and Clinical Developments
finance.yahoo.com - May 22 at 9:29 AM
marketbeat.com logoPluristem reports 3Q loss
marketbeat.com - May 9 at 6:01 AM
americanbankingnews.com logo-$0.07 Earnings Per Share Expected for Pluristem Therapeutics Inc. (PSTI) This Quarter
www.americanbankingnews.com - May 8 at 1:12 PM
americanbankingnews.com logoHC Wainwright Reiterates Buy Rating for Pluristem Therapeutics Inc. (PSTI)
www.americanbankingnews.com - May 7 at 10:02 AM
americanbankingnews.com logoPluristem Therapeutics Inc. (PSTI) Rating Reiterated by Maxim Group
www.americanbankingnews.com - May 7 at 7:34 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Reports Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome
www.streetinsider.com - May 4 at 12:41 AM
finance.yahoo.com logoPluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome
finance.yahoo.com - May 3 at 7:39 PM
americanbankingnews.com logoPluristem Therapeutics (PSTI) Earns Media Impact Rating of 0.31
www.americanbankingnews.com - May 3 at 6:54 PM
americanbankingnews.com logoPluristem Therapeutics (PSTI) Earning Somewhat Critical News Coverage, Study Finds
www.americanbankingnews.com - April 28 at 12:39 PM
americanbankingnews.com logoPluristem Therapeutics Inc. (PSTI) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 28 at 10:18 AM
prnewswire.com logoHow These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion Pharma - PR Newswire (press release)
www.prnewswire.com - April 28 at 8:15 AM
americanbankingnews.com logoPluristem Therapeutics (PSTI) Receiving Somewhat Favorable Media Coverage, Study Shows
www.americanbankingnews.com - April 24 at 7:48 PM
americanbankingnews.com logoPluristem Therapeutics (PSTI) Earning Somewhat Negative Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 21 at 5:46 PM
feeds.benzinga.com logoPluristem Reaches Milestone of 100 Granted Patents, Including Coverage of Leading Indications in Major Markets
feeds.benzinga.com - April 19 at 8:58 AM
americanbankingnews.com logoPluristem Therapeutics (PSTI) Getting Somewhat Positive Press Coverage, Analysis Shows
www.americanbankingnews.com - April 18 at 9:15 PM
americanbankingnews.com logo Analysts Anticipate Pluristem Therapeutics Inc. (PSTI) to Announce -$0.07 Earnings Per Share
www.americanbankingnews.com - April 17 at 3:02 PM
americanbankingnews.com logoPluristem Therapeutics Inc. (PSTI) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 13 at 3:04 PM
nasdaq.com logoPluristem Therapeutics (PSTI) Shares March Higher, Can It Continue? - Nasdaq
www.nasdaq.com - April 8 at 12:03 PM
finance.yahoo.com logoPluristem Therapeutics (PSTI) Shares March Higher, Can It Continue?
finance.yahoo.com - April 7 at 12:04 PM
finance.yahoo.com logo$54 Billion Boost in U.S. Defense Budget Comes as Pluristem's Radiation Antidote Nears FDA Approval
finance.yahoo.com - April 3 at 9:05 AM
streetinsider.com logoPluristem Therapeutics (PSTI), Sosei CVC Advance Towards Finalizing JV for Commercialization of PLX-PAD in Japan
www.streetinsider.com - March 31 at 12:40 AM
us.rd.yahoo.com logoPluristem and Sosei CVC Advancing Towards Finalizing Joint Venture for the Commercialization of PLX-PAD in Japan
us.rd.yahoo.com - March 31 at 12:40 AM
streetinsider.com logoPluristem Therapeutics (PSTI), Sosei CVC Advance Towards Finalizing JV for Commercialization of PLX-PAD in Japan - StreetInsider.com
www.streetinsider.com - March 30 at 7:38 PM
biz.yahoo.com logoPLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 30 at 7:38 PM
streetinsider.com logoPluristem Therapeutics (PSTI) Announces Co-CEO Structure and ... - StreetInsider.com
www.streetinsider.com - March 30 at 1:09 AM
biz.yahoo.com logoPLURISTEM THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of I
us.rd.yahoo.com - March 29 at 8:08 PM
reuters.com logoEU rapid drug approval plan worries some national agencies
www.reuters.com - March 29 at 8:58 AM
americanbankingnews.com logoPluristem Therapeutics Inc. (PSTI) Given a $4.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 26 at 9:46 PM
finance.yahoo.com logoPLURISTEM THERAPEUTICS INC Financials
finance.yahoo.com - February 14 at 11:55 PM
finance.yahoo.com logoPluristem Therapeutics downgraded by Maxim Group
finance.yahoo.com - February 14 at 3:16 AM
us.rd.yahoo.com logoPluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook
us.rd.yahoo.com - February 13 at 9:04 AM
biz.yahoo.com logoPLURISTEM THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - February 8 at 9:25 PM
finance.yahoo.com logoPluristem Announces Closing of Bought Offering and Underwriter’s Exercise in Full of Over-Allotment Option
finance.yahoo.com - January 26 at 2:19 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Increases Bought Deal Offering of Common Stock and Warrants to $15M - StreetInsider.com
www.streetinsider.com - January 21 at 1:17 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Increases Bought Deal Offering of Common Stock and Warrants to $15M
www.streetinsider.com - January 20 at 8:15 PM
us.rd.yahoo.com logoPluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000
us.rd.yahoo.com - January 20 at 8:15 PM
biz.yahoo.com logoPLURISTEM THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
biz.yahoo.com - January 20 at 8:15 PM
us.rd.yahoo.com logoPluristem Announces Bought Deal Offering
us.rd.yahoo.com - January 20 at 6:20 AM
us.rd.yahoo.com logo4:55 pm Pluristem Therapeutics announces $10 mln bought deal offering
us.rd.yahoo.com - January 20 at 6:20 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Reports Clearance in Germany to Initiate Phase III Trial of PLX-PAD Cells in CLI - StreetInsider.com
www.streetinsider.com - January 18 at 8:26 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Reports Clearance in Germany to Initiate Phase III Trial of PLX-PAD Cells in CLI
www.streetinsider.com - January 17 at 7:45 PM
finance.yahoo.com logoFlood of News Presents Buying Opportunity
finance.yahoo.com - January 17 at 7:45 PM
finance.yahoo.com logoPluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval
finance.yahoo.com - January 17 at 10:54 AM
finance.yahoo.com logo6:05 am Pluristem Therapeutics receives clearance in Germany to initiate Phase III trial of PLX-PAD cells to treat Critical Limb Ischemia
finance.yahoo.com - January 17 at 10:54 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Completes Phase II PLX-PAD Patient Enrollment
www.streetinsider.com - January 12 at 8:00 PM

Social

Chart

Pluristem Therapeutics (PSTI) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff